Beung‐Chul Ahn

Ulsan College — South Korea

Medicine · Health Sciences

14h-index942citations67works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(40), Cancer Immunotherapy and Biomarkers(22), Lung Cancer Research Studies(21), Cancer Genomics and Diagnostics(14), Pancreatic and Hepatic Oncology Research(10)

Publications67 total

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced <i>ROS1</i> -Positive Non−Small Cell Lung Cancer
JAMA Oncology·2025Open Access
408 Treatment patterns and clinical outcomes of patients with resectable NSCLC receiving neoadjuvant immunochemotherapy with or without adjuvant immunotherapy: a real-world single-center study
Regular and Young Investigator Award Abstracts·2025Open Access
2624P Artificial intelligence (AI)-powered immune phenotype (IP) predicts differential benefit from nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in advanced clear cell renal cell carcinoma (ccRCC)
Annals of Oncology·2025
VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR‐Tyrosine Kinase Inhibitor‐Resistant Non‐Small Cell Lung Cancer
MedComm·2025Open Access
Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor–tyrosine kinase inhibitor resistance subclones
Experimental & Molecular Medicine·2025· 1 citedOpen Access
Abstract 3264: Digital profiling of tumor-derived extracellular vesicle RNA: a novel approach for early diagnosis and monitoring of pancreatic cancer patients
Cancer Research·2025
A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
Nature Communications·2024· 7 citedOpen Access
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
OncoImmunology·2024· 2 citedOpen Access
Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Promising Screening Biomarkers for Brain Metastases in Patients with Lung Cancer
International Journal of Molecular Sciences·2024· 4 citedOpen Access
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.
Journal of Clinical Oncology·2024· 8 cited
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18.
Journal of Clinical Oncology·2024
99TiP A randomized phase II study of lazertinib alone versus lazertinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history
ESMO Open·2024Open Access
Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy
Cancers·2024· 5 citedOpen Access
Complete Remission of Dural-Based Leptomeningeal Metastasis in Patient With Non-Small Cell Lung Cancer by Osimertinib
Brain Tumor Research and Treatment·2024· 1 citedOpen Access
Treatment Outcomes of Proton Beam Therapy for Esophageal Squamous Cell Carcinoma at a Single Institute
Cancers·2023· 4 citedOpen Access
Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression
Cancers·2023· 2 citedOpen Access
Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non–Small Cell Lung Cancer
Cancer Research and Treatment·2023· 3 citedOpen Access
Nivolumab after cyclophosphamide and doxorubicin induction chemotherapy in previously treated patients with EGFR or ALK wild type non-squamous cell non-small cell lung cancer with less than 10% of PD-L1 expression
Research Square (Research Square)·2023· 1 citedOpen Access
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study
Lung Cancer·2023· 9 citedOpen Access
Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer
Cancer Research·2023
page 1 of 4Next →

Frequent Co-authors

Min Hee Hong(31), Byoung Chul Cho(25), Hye Ryun Kim(20), Kyoung‐Ho Pyo(15), Sun Min Lim(15), Youngjoo Lee(11), Chang Gon Kim(8), Charny Park(8), Hyo Sup Shim(7), Se Hwa Hong(7), Seong Gu Heo(6), Namhee Yu(6), Ji‐Youn Han(6), Geon Kook Lee(6), Hong In Yoon(5), Dongmin Jung(5), Chun‐Bong Synn(5), Mi Ran Yun(5), Jae Hwan Kim(5), Wongeun Lee(5)